However, trametinib failed to rescue a multi-targeting CRC model that combined oncogenic RasG12V plus RNAi (“i”) knockdown of Apci and P53i (RAP; Fig. 1A; all transgenes in this study are targeted to the hindgut via the byn-GAL4 transcriptional driver). This evidence concerns the gene LRPAP1 and colorectal carcinoma.